WV UK Development v Rui Liu: High Court sets aside Norwich Pharmacal disclosure order

The High Court has set aside an order requiring disclosure of extensive financial records and witness evidence in a shareholder dispute, finding that the claimants had failed to establish a sufficient basis for the relief sought.

In WV UK Development Limited and others v Rui Liu and others [2026] EWHC 2715 (BP), Christopher Pymont KC held that the Norwich Pharmacal jurisdiction could not be used to investigate whether additional causes of action might exist where the claimants had not demonstrated a good arguable case of the alleged wrongdoing.

The dispute arose from a property development joint venture between Vincent Wan and Rui Liu, conducted through VW-Leos Investment Holdings Limited and its subsidiaries. Wan and his associated companies had invested approximately £41m in the business. Under a shareholders’ agreement dated August 2021, Wan’s interest was 49%, while Liu held 51% indirectly through Leos UK Investment Limited.

Relations deteriorated as Wan sought financial and transactional information about the group’s investments and explored an exit from the joint venture. Despite repeated requests, including correspondence from solicitors and a formal letter before action threatening an unfair prejudice petition under section 994 of the Companies Act 2006, the information was not provided in the form sought.

The dispute intensified after the claimants discovered that Leos UK had been dissolved and that a confirmation statement filed at Companies House appeared to record the transfer of its shareholding in the joint venture company to its parent, Leos Investment Holdings Limited, without the required shareholder consent.

The claimants subsequently obtained an order without notice under the court’s Norwich Pharmacal jurisdiction, requiring disclosure of extensive financial records dating back to 2020 and a witness statement explaining the dissolution and apparent share transfer. The defendants applied to have the order set aside or varied.

Pymont KC accepted that the claimants had initially had a good arguable case that the apparent share transfer breached the shareholders’ agreement. However, the evidence subsequently indicated that no executed transfer, sale agreement or payment had taken place. Leos UK was restored to the register in May 2026, with section 1028 of the Companies Act 2006 deeming it to have continued in existence as if it had not been dissolved.

The court considered that these developments substantially weakened the alleged contractual breach, although it did not finally determine the underlying issues. More importantly, the alleged unauthorised dealing with shares did not establish a connection to the separate allegation that the company’s assets or Wan’s investment had been dissipated.

The judge found a serious mismatch between the claim relied upon to obtain relief and the extensive disclosure sought. The claimants were effectively seeking to investigate whether other claims might exist, rather than obtaining information necessary to advance an established arguable case. The application therefore amounted to a fishing expedition.

The application also failed to satisfy the relevant requirements for Norwich Pharmacal relief. The company was not shown to have facilitated the alleged contractual wrongdoing, while the individuals said to have been involved did not have the immediate access to the financial records sought. The judge further considered that the claimants could pursue their concerns through substantive proceedings, including a potential unfair prejudice petition, in which disclosure could be sought through the ordinary procedural mechanisms.

The court also criticised the decision to proceed without notice. There had been sufficient time to notify the defendants, and the evidence did not establish a real risk that they would destroy the documents. Concerns about possible dissipation were of limited relevance because the application did not seek a freezing order.

Pymont KC accordingly set aside the Chief Master’s order. The decision reinforces the limits of Norwich Pharmacal relief, emphasising that it is intended to assist the vindication of an arguable legal claim, not to provide a broad investigative mechanism where the existence of further wrongdoing remains speculative.